The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

29 Apr 2010 09:02

RNS Number : 0230L
e-Therapeutics plc
29 April 2010
 



e-Therapeutics plc

('e-Therapeutics' or 'the Company')

 

Issue of Equity and Director's award of Options

 

e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, announces that on 28 April 2010 , the Company issued and allotted 466,460 ordinary shares of 0.1p each in the Company (' Ordinary Shares') in order to satisfy the exercise of certain options.

 

Application has been made to admit the new Ordinary Shares to trading on AIM and dealings in the new Ordinary Shares are expected to commence on 5 May 2010. Following admission the number of Ordinary Shares in issue in the Company will be 65,886,752.

 

The above figure (65,886,752 Ordinary Shares) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the FSA's Disclosure and Transparency Rules.

 

In addition to the above, two directors of the Company being Mr Oliver James and Mr Brad Hoy were both granted option over 25,000 ordinary shares in the Company at an exercise price of £0.385 and which have a vesting period of 3 years. Following this grant Mr James and Mr Hoy have the following interests in ordinary shares of the Company:

 

Name

Ordinary Shares owned

Options over Ordinary Shares

Number

Number

Exercise Price

Date at which exercisable

Oliver James

38,500

118,020

£0.67

Vested

25,000

£0.385

28 April 2013

Brad Hoy

80,000

£0.375

Vested

25,000

£0.385

28 April 2013

 

 

 

- Ends -

 

 

For more information:

e-Therapeutics plc

www.etherapeutics.co.uk

Malcolm Young

malcolm@etherapeutics.co.uk

+44 (0) 191 233 1317

Nominated Advisor & Broker:

Canaccord Adams Ltd

www.canaccordadams.com

Robert Finlay / Henry Fitzgerald-O'Connor

henry.fitzgerald-o'connor@canaccordadams.com

+44 (0) 20 7050 6500

Media enquiries:

Abchurch Communications

www.abchurch-group.com

Heather Salmond / Simone Elviss / Hannah Sharman

simone.elviss@abchurch-group.com

+44 (0) 20 7398 7700

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOESEFSAUFSSESL
Date   Source Headline
12th Apr 20227:00 amRNSKey Milestone Achieved on Galapagos Collaboration
5th Apr 20227:00 amRNSImmuno-Oncology Research Collaboration with iTeos
16th Feb 20224:41 pmRNSHolding(s) in Company
16th Feb 202211:47 amRNSHolding(s) in Company
15th Feb 20223:27 pmRNSHolding(s) in Company
31st Jan 20227:00 amRNSTotal Voting Rights
20th Jan 202210:58 amRNSNew Corporate Website
18th Jan 20224:41 pmRNSHolding(s) in Company
7th Jan 20227:00 amRNSDirector Dealing and Issue of Equity
22nd Nov 20217:00 amRNSSenior Management Update
26th Oct 20211:55 pmRNSDirector Dealing
26th Oct 20217:01 amRNSInterim results for six months ended 31 July 2021
26th Oct 20217:00 amRNSRNAi Platform Characterisation Results
20th Oct 20217:00 amRNSInvestor Presentation
11th Oct 20217:05 amRNSPatent Filing Applications
11th Oct 20217:00 amRNSNotice of Interim Results
24th Sep 20217:00 amRNSCommencement of trading on the OTCQX Best Market
2nd Sep 20214:41 pmRNSSecond Price Monitoring Extn
2nd Sep 20214:35 pmRNSPrice Monitoring Extension
30th Jul 20217:00 amRNSTotal Voting Rights
6th Jul 20217:00 amRNSDirector Dealing and Issue of Equity
2nd Jul 20217:00 amRNSFurther milestone in Galapagos collaboration
30th Jun 20217:00 amRNSTotal Voting Rights
21st Jun 20213:13 pmRNSHolding(s) in Company
21st Jun 20217:00 amRNSHolding(s) in Company
18th Jun 202112:52 pmRNSHolding(s) in Company
17th Jun 20213:44 pmRNSHolding(s) in Company
16th Jun 20211:27 pmRNSResult of AGM
2nd Jun 20217:00 amRNSSenior Management Appointment and Options Grant
21st May 20217:00 amRNSNotice of AGM and Posting of Annual Report
14th May 20217:00 amRNSResults of conditional Fundraise to raise £22.5m
13th May 20214:50 pmRNSRetail Offer
13th May 20214:45 pmRNSProposed Fundraise in excess of £20 million
13th May 20217:00 amRNSFinal Results for the Year Ended 31 January 2021
6th May 20217:00 amRNSNotification of Full Year Results Date
23rd Apr 20217:00 amRNSETX to receive two payments from Galapagos
29th Mar 20217:00 amRNSAppointment of Chief Financial Officer
1st Mar 20217:00 amRNSChange of Adviser
1st Mar 20217:00 amRNSBoard Changes
25th Feb 20213:29 pmRNSHolding(s) in Company
16th Feb 20217:00 amRNSe-therapeutics to present at Shares Evening
10th Feb 20214:35 pmRNSHolding(s) in Company
1st Feb 20217:00 amRNSRNA Therapeutics Platform
28th Jan 20214:40 pmRNSSecond Price Monitoring Extn
28th Jan 20214:35 pmRNSPrice Monitoring Extension
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:36 pmRNSPrice Monitoring Extension
12th Jan 202111:24 amRNSHolding(s) in Company
4th Jan 20214:31 pmRNSDirector/PDMR Shareholding
18th Dec 20205:44 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.